Recombinant Mouse Siglec-H Fc Chimera Protein, CF

2 μg/lane of Recombinant Mouse Siglec-H Fc Chimera (Catalog # 10264-SH) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 71-81 kDa and 140-160 kDa, respectively.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse Siglec-H Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse Siglec‑H Fc Chimera (Catalog # 10264-SH) is immobilized at 2 μg/mL (100 μL/well), the concentration of Recombinant Mouse Siglec‑3 Fc Chimera (Catalog # 10102-SL) that produces 50% of the optimal binding response is 5-20 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse Siglec-H protein
  

  Mouse Siglec-H (Asn19-Gly269) Accession # NP_848821.2	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: NP_848821.2
• N-terminal Sequence:

  Asn19

• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW:

  55 kDa

  .
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 71-81 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse Siglec-H Fc Chimera Protein, CF

• 6430529G09Rik
• Siglech sialic acid binding Ig-like lectin H
• SiglecH
• Siglec-H

Background

Siglecs (sialic acid-binding Ig-like lectins) are I-type (Ig-type) lectins belonging to the Ig superfamily (1, 2). They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding, followed by varying numbers of Ig-like C2-type domains (3, 4). Siglec 5 to 11 are collectively referred to as CD33-related Siglecs due to their high degree of sequence similarity with CD33/Siglec-3 both in their extracellular and intracellular regions. One remarkable feature of the CD33-related Siglecs is their differential expression pattern within the hematopoietic system (4, 5). Mouse Siglec-H is an endocytic receptor expressed predominantly on a specialized subset of leukocytes, the plasmacytoid dendritic cell (pDC). Siglec-H has not been shown to bind sialic acids (6). Unlike other CD33-related siglecs, the cytoplasmic tail of Siglec-H lacks ITIM-related sequence (6, 7). The transmembrane region contains a charged lysine residue that could associate with DAP12 which reduces interferon-alpha (IFN alpha ) production (6, 8).

1. Crocker, P.R. et al. (1998) Glycobiology 8:v.
2. Powell, L.D. et al. (1995) J. Biol. Chem. 270:14243.
3. May, A.R. et al. (1998) Mol. Cell (1998) 1:719.
4. Crocker, P.R. and A. Varki (2001) Trends Immunol. 22:337.
5. Crocker, P.R. et al. (2001) Immunology 103:137.
6. Zhang, J. et al. (2006) Blood 107:3600.
7. Blasius, A.L. and M. Colonna (2006) Trends Immunol. 27:255.
8. Blasius, A.L. et al. 2006. Blood 107:2474.

Bioinformatics

• Uniprot:
  • NP_848821.2()